← Leaderboards
Marc Joseph Gurwith
Paxvax, Inc.
$21,974,740
Attributed
$25,653,123
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.1M · FY2010–16$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$25,653,123 · 5
By mechanism
N01$20,060,548 · 1
R44$4,743,753 · 2
R43$848,822 · 2
Top collaborators
- Jeffery Alexander7 shared
- Timothy Mayall4 shared
- Jonathan Smith4 shared
Most similar at Paxvax, Inc.
Same institution · by research overlap
- Jeffery Alexander$1,764,192
- Timothy Mayall$894,281
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesVaccine DeliveryTechnologyResponseVaccine DevelopmentSiteProteinsSmall Business Innovation Research GrantPreventOral CavityImmunogenicityLifeProductionBaseAntibodiesNeutralizing AntibodyImmune ResponseMeasles VaccineAnimalsEnv Gene ProductsOryctolagus CuniculusPoliomyelitisAcquired Immunodeficiency SyndromeAdenoviruses
Grant awards (15)
HIV B-Cell Lineage Vaccine Design Based on Replicating SAd and Env Protein in NHP$971,055
R44 · FY2016 · AI
Development of Technologies to Facilitate the use and Response of Vaccines$593,314
N01 · FY2016 · AI · contact PI
HIV B-Cell Lineage Vaccine Design Based on Replicating SAd and Env Protein in NHP$801,463
R44 · FY2015 · AI
Development of Technologies to Facilitate the use and Response of Vaccines$698,949
N01 · FY2015 · AI · contact PI
Oral, replicating Ad4-HIV vaccine development & evaluation in NHP challenge model$971,235
R44 · FY2014 · AI · contact PI
Development of Technologies to Facilitate the use and Response of Vaccines$651,370
N01 · FY2014 · AI · contact PI
Development of Technologies to Facilitate the use and Response of Vaccines$10,792,404
N01 · FY2013 · AI · contact PI
Oral, replicating Ad4-HIV vaccine development & evaluation in NHP challenge model$1,000,000
R44 · FY2013 · AI · contact PI
Replicating Ad4-HIV vaccine development based on improved HIV Env and GBV-C E2$287,214
R43 · FY2013 · AI
Development of Technologies to Facilitate the use and Response of Vaccines$1,651,037
N01 · FY2012 · AI · contact PI
Oral, replicating Ad4-HIV vaccine development & evaluation in NHP challenge model$1,000,000
R44 · FY2012 · AI · contact PI
Replicating Ad4-HIV vaccine development based on improved HIV Env and GBV-C E2$261,608
R43 · FY2012 · AI
Development of Technologies to Facilitate the use and Response of Vaccines$1,869,229
N01 · FY2011 · AI · contact PI
Development of Technologies to Facilitate the use and Response of Vaccines$3,804,245
N01 · FY2010 · AI · contact PI
Ad4 vectored HIV-Env vaccines with improved immunogenicity$300,000
R43 · FY2010 · AI · contact PI